The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Regulation of Tumor Angiogenesis by EZH2
Open accessAbstract
SUMMARY While VEGF-targeted therapies are showing promise, new angiogenesis targets are needed to make additional gains. Here, we show that increased Zeste homologue 2 (EZH2) expression in either tumor cells or in tumor vasculature is predictive of poor clinical outcome. The increase in endothelial EZH2 is a direct result of VEGF stimulation by a paracrine circuit that promotes angiogenesis by methylating and silencing vasohibin1 (VASH1). EZH2 silencing in the tumor-associated endothelial cells inhibited angiogenesis mediated by reactivation of VASH1, and reduced ovarian cancer growth, which is further enhanced in combination with EZH2 silencing in tumor cells. Collectively, these data support the potential for targeting EZH2 as an important therapeutic approach. SIGNIFICANCE In this work, we identify EZH2 as a key regulator of tumor angiogenesis. The increase in endothelial EZH2 is a direct result of VEGF stimulation and indicates the presence of a paracrine circuit that promotes angiogenesis. EZH2 silencing in the tumor-associated endothelial cells using siRNA, packaged in the chitosan delivery system, resulted in significant growth inhibition in an orthotopic ovarian cancer model. EZH2 silencing in tumor endothelial cells resulted in decreased angiogenesis that was mediated by increased levels of the angiogenesis inhibitor, vasohibin1 (VASH1). Combined, these data provide a significant conceptual advance in our understanding of the regulation of angiogenesis in ovarian carcinoma and support the potential for targeting EZH2 as a therapeutic approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
A review of chitin and chitosan applications
Ravi Kumar, M. N. V. (2000) · Reactive and Functional Polymers · doi:10.1016/s1381-5148(00)00038-9 · Cited by 6,009
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Lu, C., Jennings, N. B., Armaiz-Pena, G., Bankson, J. A., Ravoori, M., et al. (2006) · Nature Medicine · doi:10.1038/nm1447 · Cited by 1,320 · cited 2×
“We have recently demonstrated that a neutral nanoliposomal carrier allows efficient systemic delivery of siRNA into orthotopic tumors (Landen et al., 2005; Thaker et al., 2006).”
BackgroundSelf-citationLessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
McCarty, K. S., MILLER, L. S., Cox, E. B., Konrath, J. G., & McCarty, K. S. (1985) · PubMed · Cited by 1,027
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3
Cao, R., & Zhang, Y. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.02.001 · Cited by 914
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Relf, M., LeJeune, S., Scott, P. A. E., Fox, S. B., Smith, K. A., Leek, R., Moghaddam, A., Whitehouse, R. M., Bicknell, R., & Harris, A. L. (1997) · PubMed · Cited by 833
Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer
Merritt, W. M., Lin, Y. G., Han, L. Y., Kamat, A. A., Spannuth, W. A., Schmandt, R., Urbauer, D., Pennacchio, L. A., Cheng, J.-F., Nick, A. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803785 · Cited by 712
Self-citationTherapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
Self-citationWright, G. W., & Simon, R. M. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btg345 · Cited by 665
RNA Interference in Vitro and in Vivo Using a Novel Chitosan/siRNA Nanoparticle System
Howard, K. A., Rahbek, U. L., Liu, X., Damgaard, C. K., Glud, S. Z., Andersen, M. Ø., Hovgaard, M. B., Schmitz, A., Nyengaard, J. R., Besenbacher, F., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.04.010 · Cited by 585
Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3
Cha, T.-L., Zhou, B. P., Xia, W., Wu, Y., Yang, C.-C., Chen, C.-T., Ping, B., Otte, A. P., & Hung, M.-C. (2005) · Science · doi:10.1126/science.1118947 · Cited by 548
Self-citationStress hormone-mediated invasion of ovarian cancer cells
Sood, A. K., Bhatty, R., Kamat, A. A., Landen, C. N., Han, L., Thaker, P. H., Li, Y., Gershenson, D. M., Lutgendorf, S., & Cole, S. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1698 · Cited by 491
Self-citationRepression and activation by multiprotein complexes that alter chromatin structure.
Kingston, R. E., Bunker, C. A., & Imbalzano, A. N. (1996) · Genes & Development · doi:10.1101/gad.10.8.905 · Cited by 443
Des Guetz, G., Uzzan, B., Nicolas, P., Cucherat, M., Morere, J.-F., Benamouzig, R., Breau, J.-L., & Perret, G.-Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603176 · Cited by 406
Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis
Watanabe, K., Hasegawa, Y., Yamashita, H., Shimizu, K., Ding, Y., Abe, M., Ohta, H., Imagawa, K., Hojo, K., Maki, H., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421152 · Cited by 317
Halder, J., Kamat, A. A., Landen, C. N., Han, L. Y., Lutgendorf, S. K., Lin, Y. G., Merritt, W. M., Jennings, N. B., Chavez-Reyes, A., Coleman, R. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0021 · Cited by 297
Self-citationLocking in stable states of gene expression: transcriptional control during Drosophila development
Simon, J. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80093-x · Cited by 281
Merritt, W. M., Lin, Y. G., Spannuth, W. A., Fletcher, M. S., Kamat, A. A., Han, L. Y., Landen, C. N., Jennings, N., De Geest, K., Langley, R. R., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn024 · Cited by 257
Self-citationBiological Significance of Focal Adhesion Kinase in Ovarian Cancer
Sood, A. K., Coffin, J. E., Schneider, G. B., Fletcher, M. S., DeYoung, B. R., Gruman, L. M., Gershenson, D. M., Schaller, M. D., & Hendrix, M. J. C. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63370-6 · Cited by 248
Self-citationKerbel, R. S., Yu, J., Tran, J., Man, S., Viloria-Petit, A., Klement, G., Coomber, B. L., & Rak, J. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013172910858 · Cited by 237
Matsukawa, Y., Semba, S., Kato, H., Ito, A., Yanagihara, K., & Yokozaki, H. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00203.x · Cited by 212
Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder
Raman, J. D., Mongan, N. P., Tickoo, S. K., Boorjian, S. A., Scherr, D. S., & Gudas, L. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1047 · Cited by 193
Burger, R. A., Brady, M. F., Bookman, M. A., Walker, J. L., Homesley, H. D., Fowler, J., Monk, B. J., Greer, B. E., Boente, M., & Liang, S. X. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.18_suppl.lba1 · Cited by 186
Lu, C., Bonome, T., Li, Y., Kamat, A. A., Han, L. Y., Schmandt, R., Coleman, R. L., Gershenson, D. M., Jaffe, R. B., Birrer, M. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3700 · Cited by 182
Self-citationYonghua, Z., Kunlin, J., Ou Mao, X., & Greenberg, D. A. (2003) · The FASEB Journal · doi:10.1096/fj.02-0515com · Cited by 180
Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0274 · Cited by 171
Chromo-domain proteins: linking chromatin structure to epigenetic regulation
Cavalli, G., & Paro, R. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80011-2 · Cited by 169
Angiogenesis as a strategic target for ovarian cancer therapy
Spannuth, W. A., Sood, A. K., & Coleman, R. L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1051 · Cited by 162
Self-citationMetronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer
Kamat, A. A., Kim, T. J., Landen, C. N., Lu, C., Han, L. Y., Lin, Y. G., Merritt, W. M., Thaker, P. H., Gershenson, D. M., Bischoff, F. Z., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3282 · Cited by 162
Self-citationDonninger, H., Bonome, T., Radonovich, M., Pise-Masison, C. A., Brady, J. N., Shih, J. H., Barrett, J. C., & Birrer, M. J. (2004) · Oncogene · doi:10.1038/sj.onc.1207959 · Cited by 157
Self-citationFunctional significance of VEGFR‐2 on ovarian cancer cells
Spannuth, W. A., Nick, A. M., Jennings, N. B., Armaiz-Peña, G. N., Mangala, L. S., Danes, C. G., Lin, Y. G., Merritt, W. M., Thaker, P. H., Kamat, A. A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24028 · Cited by 153
Self-citationWeikert, S., Christoph, F., Köllermann, J. W., Müller, M., Schrader, M. G., Miller, K., & Krause, H. (2005) · International Journal of Molecular Medicine · doi:10.3892/ijmm.16.2.349 · Cited by 151
Langley, R. R., Ramirez, K. M., Tsan, R. Z., Arsdall, M. R. V., Nilsson, M. B., & Fidler, I. J. (2003) · PubMed · Cited by 144
Self-citationConnective tissue growth factor (CTGF) and cancer progression
Chu, C., Chang, C.-C., Prakash, E., & Kuo, M. (2008) · Journal of Biomedical Science · doi:10.1007/s11373-008-9264-9 · Cited by 142
Connective tissue growth factor: Context‐dependent functions and mechanisms of regulation
Cicha, I., & Goppelt‐Struebe, M. (2009) · BioFactors · doi:10.1002/biof.30 · Cited by 134
Wu, Z., Zheng, S., Li, Z. M., Qiao, Y., Aau, M. Y., & Yu, Q. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.162 · Cited by 132
McGarvey, K. M., Greene, E., Fahrner, J. A., Jenuwein, T., & Baylin, S. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2029 · Cited by 127
Ino, K., Shibata, K., Kajiyama, H., Yamamoto, E., Nagasaka, T., Nawa, A., Nomura, S., & Kikkawa, F. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602961 · Cited by 125
Vasohibin-1 Expression in Endothelium of Tumor Blood Vessels Regulates Angiogenesis
Hosaka, T., Kimura, H., Heishi, T., Suzuki, Y., Miyashita, H., Ohta, H., Sonoda, H., Moriya, T., Suzuki, S., Kondo, T., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080788 · Cited by 107
Kidani, K., Osaki, M., Tamura, T., Yamaga, K., Shomori, K., Ryoke, K., & Ito, H. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2008.03.016 · Cited by 107
Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis
Huang, J., Soffer, S. Z., Kim, E. S., McCrudden, K. W., Huang, J. T., New, T. N., Manley, C. A., Middlesworth, W., O’Toole, K., Yamashiro, D. J., et al. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.36.2.1 · Cited by 101
Shen, J., Yang, X.-R., Xiao, W., Hackett, S. F., Sato, Y., & Campochiaro, P. A. (2006) · The FASEB Journal · doi:10.1096/fj.05-5046fje · Cited by 91
Dual Targeting of Endothelial Cells and Pericytes in Antivascular Therapy for Ovarian Carcinoma
Lü, C., Kamat, A. A., Lin, Y. G., Merritt, W. M., Landen, C. N., Kim, T. J., Spannuth, W. A., Arumugam, T., Han, L. Y., Jennings, N. B., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0197 · Cited by 90
Self-citationEphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma
Lee, J., Han, H. D., Shahzad, M. M. K., Kim, S. W., Mangala, L. S., Nick, A. M., Lü, C., Langley, R. R., Schmandt, R. E., Kim, H., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp231 · Cited by 90
Self-citationCollateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
Stone, R. L., Sood, A. K., & Coleman, R. L. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70362-6 · Cited by 80
Self-citationTonini, T., D’Andrilli, G., Fucito, A., Gaspa, L., & Bagella, L. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21241 · Cited by 75
Ptasinska, A., Wang, S., Zhang, J., WESLEY, R. A., & Danner, R. L. (2006) · The FASEB Journal · doi:10.1096/fj.06-6822com · Cited by 69
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer
Lü, C., Thaker, P. H., Lin, Y. G., Spannuth, W. A., Landen, C. N., Merritt, W. M., Jennings, N. B., Langley, R. R., Gershenson, D. M., Yancopoulos, G. D., et al. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.12.028 · Cited by 62
Self-citationAli‐Fehmi, R., Morris, R. T., Bandyopadhyay, S., Che, M., Schimp, V. L., Malone, J. M., & Munkarah, A. R. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.10.587 · Cited by 55
Self-citationMolecular and Physiologic Mechanisms of Drug Resistance in Cancer: An Overview
Kerbel, R. S. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013129128673 · Cited by 30
Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo
Kern, J., Steurer, M., Gastl, G. A., Gunsilius, E., & Untergasser, G. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-284 · Cited by 30
Cited by
Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471
SWI/SNF nucleosome remodellers and cancer
Wilson, B. G., & Roberts, C. W. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3068 · Cited by 1,282
Cancer epigenetics reaches mainstream oncology
Rodríguez-Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,205
EZH2: a novel target for cancer treatment
Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 926
Paraneoplastic thrombocytosis in ovarian cancer
Stone, R. L., Nick, A. M., McNeish, I. A., Balkwill, F., Han, H. D., Bottsford-Miller, J., Rupaimoole, R., Armaiz-Pena, G. N., Pecot, C. V., Coward, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110352 · Cited by 812
Self-citation
Metadata
- Authors
- Lu, C., Han, H. D., Mangala, L. S., Ali-Fehmi, R., Newton, C. S., Ozbun, L., Armaiz-Pena, G. N., Hu, W., Stone, R. L., Munkarah, A., Ravoori, M. K., Shahzad, M. M. K., Lee, J.-W., Mora, E., Langley, R. R., Carroll, A. R., Matsuo, K., Spannuth, W. A., Schmandt, R., Jennings, N. B., Goodman, B. W., Jaffe, R. B., Nick, A. M., Kim, H. S., Guven, E. O., Chen, Y.-H., Li, L.-Y., Hsu, M.-C., Coleman, R. L., Calin, G. A., Denkbas, E. B., Lim, J. Y., Lee, J.-S., Kundra, V., Birrer, M. J., Hung, M.-C., Lopez-Berestein, G., & Sood, A. K.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 18
- Issue
- 2
- Pages
- 185-197
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2152389213
- Cited by
- 399
- References
- 56
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.